Nine months after Omicron nabbed the title of newest Covid-19 virus variant, a vaccine to battle the new, more contagious variant has received a regulatory nod. But so far, only in the UK.
Moderna announced Monday that the UK signed off on its booster vaccine 1273.214, a 50 µg dose and essentially a 2-in-1. Half of the vaccine targets the original virus strain, while the other half targets Omicron (BA.1). Moderna noted that an exploratory analysis showed a “good immune response” against BA.4 and BA.5, two Omicron sub variants that have been popping up more and more frequently.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,900+ biopharma pros reading Endpoints daily — and it’s free.
